Active Biotech AB

Type: Company
Name: Active Biotech AB
Nationality: Sweden
Web Address: http://activebiotech.com/
Fact Sheet: Fact Sheet for Active Biotech AB
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Teva and Active Biotech announce encouraging data from multiple sclerosis study

Teva Pharmaceutical Industries Ltd. and Active Biotech have announced encouraging follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis, or RRMS, who were treated with laquinimod in Phase II, ... [Published Individual.com - Sep 17 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Teva And Active Biotech Announce New Follow-up Data On Laquinimod - Quick Facts

Teva Pharmaceutical Industries Ltd. (TEVA: Quote) and Active Biotech announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis or RRMS who were treated with laquinimod in Phase II, ... [Published RTTNews.com - Sep 12 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec, Merck Serono, Novartis & Teva Pharmaceutical

Research and Markets (http://www.researchandmarkets.com/research/vfkpw2/global_multiple) has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering. The Global Multiple Sclerosis Drugs market to grow ... [Published Individual.com - Sep 01 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Global Multiple Sclerosis Drugs Market 2014-2018 New Research Report

Dallas, TX -- ( ReleaseWire ) -- 08/25/2014 -- The report Global Multiple Sclerosis Drugs Market 2014-2018 says one of the emerging trends in the market is the introduction of disease-modifying drugs as a treatment option. Drugs such as Copaxone (Glatiramer ... [Published SBWire - Aug 25 2014]
First reported Aug 23 2014 - Updated Aug 23 2014 - 1 reports

Global Multiple Sclerosis Drugs Market : 2014-2018

Press ReleaseTechNavio Announces the Publication of its Research Report - Global Multiple Sclerosis Drugs Market 2014-2018TechNavio recognizes the following companies as the key players in the Global Multiple Sclerosis Drugs Market: Bayer AG, Biogen Idec ... [Published MarketResearch.com - Aug 23 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

Active Biotech Q2 net loss decreases

Active Biotech AB, a Sweden-based pharmaceutical company, has reported that net loss for the second quarter ended June 30, 2014 was SEK57.7 million, or SEK0.77 loss per share, compared to a net loss of SEK81.2 million, or SEK1.08 loss per share, for the ... [Published Individual.com - Aug 22 2014]
Entities: Active Biotech AB
First reported Aug 15 2014 - Updated Aug 15 2014 - 2 reports

Teva tries laquinimod in Huntington's after repeated MS woes

Teva Pharmaceutical ($TEVA) is rolling its troubled CNS drug laquinimod into a mid-stage study in Huntington's disease, looking to expand the potential of a treatment marked by clinical and regulatory setbacks.Active Biotech, Teva's partner on the drug, ... [Published FierceBiotech - Aug 15 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 3 reports

Teva’s immunomodulator to be tested for efficacy in Huntington’s disease clinical trial

Swedish Active Biotech AB (STO:ACTI) saidThursday that its Israeli collaborator Teva PharmaceuticalIndustries Ltd (NYSE:TEVA; TLV:TEVA) would begin a Phase II study oforal laquinimod as a therapy of Huntington's disease.The study will investigate the ... [Published MedCity News - Aug 14 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

BRIEF-Active Biotech's partner Teva initiates trial in Huntington's disease

7:39am BSTAug 14 (Reuters) - Active Biotech : * Active biotech's partner teva initiates a laquinimod clinical trial inhuntington's disease Link to press release ... [Published Reuters UK - Aug 14 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

The Launch of Five Immunomodulatory Therapies for Relapsing Forms of Multiple Sclerosis Will Contribute to 4 Percent Annual Growth of the Total Market from 2013 to 2023

BURLINGTON, Mass., Aug. 7, 2014 /PRNewswire/ -- Decision Resources Group finds that the forecast launch of Biogen Idec's Plegridy, Roche/Genentech's ocrelizumab, Biogen Idec/AbbVie's daclizumab, Teva/Active Biotech's Nerventra and Receptos' RPC-1063, ... [Published PR Newswire: General Business - Aug 07 2014]
First reported May 23 2014 - Updated May 23 2014 - 2 reports

Teva and Active Biotech to Continue with the Development of Nerventra® (Laquinimod) for Multiple Sclerosis Following Confirmation of CHMP Opinion

JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) announced today that the Committee for Medicinal Products for Human Use (CHMP) confirmed its January 23, 2014 opinion ... [Published Business Wire Science: Science News - May 23 2014]
First reported Apr 07 2014 - Updated Apr 08 2014 - 2 reports

Annual Report 2013 Active Biotech AB publ

Active Biotech 's Annual Report 2013 (in Swedish) is now available for download at www.activebiotech.com . The English version will be available within short.Related Biotechnology, Pharmaceutical and Healthcare NewsThe Annual Report will only be digitally ... [Published BioPortfolio - Apr 07 2014]

Quotes

More From BioPortfolio on "Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019"

More Content

All (49) | News (21) | Reports (0) | Blogs (6) | Audio/Video (0) | Fact Sheets (5) | Press Releases (17)
sort by: Date | Relevance
Teva and Active Biotech announce encouraging da... [Published Individual.com - Sep 17 2014]
Teva And Active Biotech Announce New Follow-up ... [Published RTTNews.com - Sep 12 2014]
Teva Presents New Clinical Safety Data in RRMS ... [Published GlobeNewswire: Acquisitions News - Sep 12 2014]
Teva Presents New Clinical Safety Data in RRMS ... [Published Business Wire Health News - Sep 12 2014]
Global Multiple Sclerosis Drugs Market 2014-201... [Published Individual.com - Sep 01 2014]
Global Multiple Sclerosis Drugs Market 2014-201... [Published SBWire - Aug 25 2014]
Global Multiple Sclerosis Drugs Market : 2014-2018 [Published MarketResearch.com - Aug 23 2014]
Active Biotech Q2 net loss decreases [Published Individual.com - Aug 22 2014]
Teva tries laquinimod in Huntington's after rep... [Published FierceBiotech - Aug 15 2014]
Active Biotech’s partner Teva starts laquinimod... [Published Nordic Life Science - Aug 15 2014]
Teva’s immunomodulator to be tested for efficac... [Published MedCity News - Aug 14 2014]
Biotech Stock Directory Update [Published InvestorIdeas.com - Aug 14 2014]
BRIEF-Active Biotech's partner Teva initiates t... [Published Reuters UK - Aug 14 2014]
Active Biotech's partner Teva initiates a laqui... [Published GlobeNewswire: Advertising News - Aug 14 2014]
Active Biotech's partner Teva initiates a laqui... [Published GlobeNewswire: Advertising News - Aug 14 2014]
Active Biotech's partner Teva initiates a laqui... [Published SPi World News - Aug 14 2014]
Active Biotech's partner Teva initiates a laqui... [Published EuroInvestor - Aug 14 2014]
Evotec AG Reports Results of First Half of 2014 [Published Virtual Strategy Magazine - Aug 12 2014]
The Launch of Five Immunomodulatory Therapies f... [Published PR Newswire: General Business - Aug 07 2014]
Active Biotech AB Interim report January-June 2014 [Published GlobeNewswire: Acquisitions News - Aug 07 2014]
Active Biotech AB Interim report January-June 2014 [Published GlobeNewswire: Acquisitions News - Aug 07 2014]
Cantargia gears up with new CEO and substantial... [Published CisionWire - English - Jun 17 2014]
Active Biotech presents data on paquinimod at E... [Published GlobeNewswire: Acquisitions News - Jun 11 2014]
Active Biotech presents data on paquinimod at E... [Published GlobeNewswire: Acquisitions News - Jun 11 2014]
Active Biotech to Present at Jefferies 2014 Hea... [Published GlobeNewswire: Acquisitions News - Jun 03 2014]
Active Biotech to Present at Jefferies 2014 Hea... [Published GlobeNewswire: Acquisitions News - Jun 03 2014]
EMA's CHMP rejects approval of multiple scleros... [Published PBR - News - May 26 2014]
Teva and Active Biotech to continue with the de... [Published GlobeNewswire: Acquisitions News - May 23 2014]
Teva and Active Biotech to Continue with the De... [Published Business Wire Science: Science News - May 23 2014]
Teva and Active Biotech to Continue with the De... [Published Business Wire Health News - May 23 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Teva Presents New Clinical Safety Data in RRMS ... [Published Business Wire Health News - Sep 12 2014]
JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) today announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting ...
The Launch of Five Immunomodulatory Therapies f... [Published PR Newswire: General Business - Aug 07 2014]
BURLINGTON, Mass., Aug. 7, 2014 /PRNewswire/ -- Decision Resources Group finds that the forecast launch of Biogen Idec's Plegridy, Roche/Genentech's ocrelizumab, Biogen Idec/AbbVie's daclizumab, Teva/Active Biotech's Nerventra and Receptos' RPC-1063, ...
Cantargia gears up with new CEO and substantial... [Published CisionWire - English - Jun 17 2014]
Cantargia, a private biopharmaceutical company developing therapeutics for the treatment of leukemia, announces that Dr. Göran Forsberg will take over the CEO position Furthermore, the company has decided to issue new shares corresponding to 20 MSEK.Cantargia ...
EMA's CHMP rejects approval of multiple scleros... [Published PBR - News - May 26 2014]
European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rejected the development of Nerventra (Laquinimod) for the treatment of relapsing-remitting multiple sclerosis (RRMS) by Israel-based Teva Pharmaceutical and Swedish ...
Teva and Active Biotech to Continue with the De... [Published Business Wire Science: Science News - May 23 2014]
JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) announced today that the Committee for Medicinal Products for Human Use (CHMP) confirmed its January 23, 2014 opinion ...
1 2

Press Releases

sort by: Date | Relevance
Teva Presents New Clinical Safety Data in RRMS ... [Published GlobeNewswire: Acquisitions News - Sep 12 2014]
Active Biotech's partner Teva initiates a laqui... [Published GlobeNewswire: Advertising News - Aug 14 2014]
Active Biotech's partner Teva initiates a laqui... [Published GlobeNewswire: Advertising News - Aug 14 2014]
Active Biotech AB Interim report January-June 2014 [Published GlobeNewswire: Acquisitions News - Aug 07 2014]
Active Biotech AB Interim report January-June 2014 [Published GlobeNewswire: Acquisitions News - Aug 07 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.